Resource Center

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:


November 8, 2012 - CML - Diagnosis and Treatment Update

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: November 08, 2012
Time: 1:00 p.m. - 2:00 p.m. ET
Location: Telephone/Web
View: Program Slides
Read: CML News Links | Transcript
Listen: Presentation  | Q&A Session
Access: Virtual Lecture 

Topics Covered

  • CML treatment options in an era of multiple approved oral therapy drugs
  • Discussion points between patients and their healthcare teams to help with treatment decisions
  • The importance of monitoring treatment response and follow-up screenings
  • Psychosocial aspects of living with a chronic cancer
  • Resources to help patients manage the impact of costs associated with CML treatment


Neil P. Shah, MD, PhD
Associate Professor in Residence
Edward S. Ageno Distinguished Professor of Hematology/Oncology
, Hematopoietic Malignancies Program
Helen Diller Family Comprehensive Cancer Center at University of California at San Francisco
San Francisco, CA

Questions Asked by the CML Community

  • What have the long-term responses been of people who stop taking any oral medication (tyrosine kinase inhibitors)?
  • For a patient who has had a 3 log reduction, is it possible, at any point, to go into remission?
  • In a study mentioned in this program, why did 45% of study patients, who are no longer on imatinib, leave the program? Did they stop taking Gleevec or did they leave for medical reasons?
  • Should a patient try a new drug if side effects from Gleevec are too difficult to manage?
  • If a patient has been on Gleevec for four years and all tests from the beginning have shown a major molecular response but never a complete molecular response, should he or she be looking for an alternative drug treatment?
  • Does Gleevec and the newer prescription drugs cross the blood-brain barrier and affect the nerve transmitters and/or cognitive functionality?
  • Is it a good idea to have a bone density test performed, as a recent study has linked bone density concerns with taking imatinib?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by grants from Novartis Oncology and Bristol-Myers Squibb.

last updated on Tuesday, November 18, 2014

Get Information
& Support

Contact an Information Specialist.